Compulsive eating and weight gain related to dopamine agonist use
Identifieur interne : 002A69 ( Istex/Corpus ); précédent : 002A68; suivant : 002A70Compulsive eating and weight gain related to dopamine agonist use
Auteurs : Melissa J. Nirenberg ; Cheryl WatersSource :
- Movement Disorders [ 0885-3185 ] ; 2006-04.
English descriptors
Abstract
Dopamine agonists have been implicated in causing compulsive behaviors in patients with Parkinson's disease (PD). These have included gambling, hypersexuality, hobbyism, and other repetitive, purposeless behaviors (“punding”). In this report, we describe 7 patients in whom compulsive eating developed in the context of pramipexole use. All of the affected patients had significant, undesired weight gain; 4 had other comorbid compulsive behaviors. In the 5 patients who lowered the dose of pramipexole or discontinued dopamine agonist treatment, the behavior remitted and no further weight gain occurred. Physicians should be aware that compulsive eating resulting in significant weight gain may occur in PD as a side‐effect of dopamine agonist medications such as pramipexole. Given the known risks of the associated weight gain and obesity, further investigation is warranted. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20757
Links to Exploration step
ISTEX:47AAA15FC13290DBB65351837B9A150C1079A72BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Compulsive eating and weight gain related to dopamine agonist use</title><author><name sortKey="Nirenberg, Melissa J" sort="Nirenberg, Melissa J" uniqKey="Nirenberg M" first="Melissa J." last="Nirenberg">Melissa J. Nirenberg</name><affiliation><mods:affiliation>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name><affiliation><mods:affiliation>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:47AAA15FC13290DBB65351837B9A150C1079A72B</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20757</idno><idno type="url">https://api.istex.fr/document/47AAA15FC13290DBB65351837B9A150C1079A72B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002A69</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Compulsive eating and weight gain related to dopamine agonist use</title><author><name sortKey="Nirenberg, Melissa J" sort="Nirenberg, Melissa J" uniqKey="Nirenberg M" first="Melissa J." last="Nirenberg">Melissa J. Nirenberg</name><affiliation><mods:affiliation>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name><affiliation><mods:affiliation>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-04">2006-04</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="524">524</biblScope><biblScope unit="page" to="529">529</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">47AAA15FC13290DBB65351837B9A150C1079A72B</idno><idno type="DOI">10.1002/mds.20757</idno><idno type="ArticleID">MDS20757</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>binge</term><term>compulsive eating</term><term>dopamine agonist</term><term>weight gain</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine agonists have been implicated in causing compulsive behaviors in patients with Parkinson's disease (PD). These have included gambling, hypersexuality, hobbyism, and other repetitive, purposeless behaviors (“punding”). In this report, we describe 7 patients in whom compulsive eating developed in the context of pramipexole use. All of the affected patients had significant, undesired weight gain; 4 had other comorbid compulsive behaviors. In the 5 patients who lowered the dose of pramipexole or discontinued dopamine agonist treatment, the behavior remitted and no further weight gain occurred. Physicians should be aware that compulsive eating resulting in significant weight gain may occur in PD as a side‐effect of dopamine agonist medications such as pramipexole. Given the known risks of the associated weight gain and obesity, further investigation is warranted. © 2005 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Melissa J. Nirenberg MD, PhD</name><affiliations><json:string>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Cheryl Waters MD, FRCP(C)</name><affiliations><json:string>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>compulsive eating</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>binge</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>weight gain</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Dopamine agonists have been implicated in causing compulsive behaviors in patients with Parkinson's disease (PD). These have included gambling, hypersexuality, hobbyism, and other repetitive, purposeless behaviors (“punding”). In this report, we describe 7 patients in whom compulsive eating developed in the context of pramipexole use. All of the affected patients had significant, undesired weight gain; 4 had other comorbid compulsive behaviors. In the 5 patients who lowered the dose of pramipexole or discontinued dopamine agonist treatment, the behavior remitted and no further weight gain occurred. Physicians should be aware that compulsive eating resulting in significant weight gain may occur in PD as a side‐effect of dopamine agonist medications such as pramipexole. Given the known risks of the associated weight gain and obesity, further investigation is warranted. © 2005 Movement Disorder Society</abstract><qualityIndicators><score>4.74</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>912</abstractCharCount><pdfWordCount>3168</pdfWordCount><pdfCharCount>20907</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>131</abstractWordCount></qualityIndicators><title>Compulsive eating and weight gain related to dopamine agonist use</title><genre><json:string>Serial article</json:string></genre><host><volume>21</volume><pages><total>6</total><last>529</last><first>524</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/mds.20757</json:string></doi><id>47AAA15FC13290DBB65351837B9A150C1079A72B</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/47AAA15FC13290DBB65351837B9A150C1079A72B/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/47AAA15FC13290DBB65351837B9A150C1079A72B/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/47AAA15FC13290DBB65351837B9A150C1079A72B/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Compulsive eating and weight gain related to dopamine agonist use</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2006</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Compulsive eating and weight gain related to dopamine agonist use</title><author><persName><forename type="first">Melissa J.</forename><surname>Nirenberg</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Weill Cornell Medical College, Department of Neurology and Neuroscience, 428 East 72nd Street, Suite 400, New York, NY 10021</p></note><affiliation>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Cheryl</forename><surname>Waters</surname><roleName type="degree">MD, FRCP(C)</roleName></persName><affiliation>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-04"></date><biblScope unit="vol">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="524">524</biblScope><biblScope unit="page" to="529">529</biblScope></imprint></monogr><idno type="istex">47AAA15FC13290DBB65351837B9A150C1079A72B</idno><idno type="DOI">10.1002/mds.20757</idno><idno type="ArticleID">MDS20757</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2006</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Dopamine agonists have been implicated in causing compulsive behaviors in patients with Parkinson's disease (PD). These have included gambling, hypersexuality, hobbyism, and other repetitive, purposeless behaviors (“punding”). In this report, we describe 7 patients in whom compulsive eating developed in the context of pramipexole use. All of the affected patients had significant, undesired weight gain; 4 had other comorbid compulsive behaviors. In the 5 patients who lowered the dose of pramipexole or discontinued dopamine agonist treatment, the behavior remitted and no further weight gain occurred. Physicians should be aware that compulsive eating resulting in significant weight gain may occur in PD as a side‐effect of dopamine agonist medications such as pramipexole. Given the known risks of the associated weight gain and obesity, further investigation is warranted. © 2005 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>dopamine agonist</term></item><item><term>compulsive eating</term></item><item><term>binge</term></item><item><term>weight gain</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-03-11">Received</change><change when="2005-08-08">Registration</change><change when="2006-04">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/47AAA15FC13290DBB65351837B9A150C1079A72B/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v21:4</doi><numberingGroup><numbering type="journalVolume" number="21">21</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2006-04">April 2006</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="140" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20757</doi><idGroup><id type="unit" value="MDS20757"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2005 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2005-03-11"></event><event type="manuscriptRevised" date="2005-07-28"></event><event type="manuscriptAccepted" date="2005-08-08"></event><event type="publishedOnlineEarlyUnpaginated" date="2005-10-31"></event><event type="firstOnline" date="2005-10-31"></event><event type="publishedOnlineFinalForm" date="2006-04-11"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-04-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">524</numbering><numbering type="pageLast">529</numbering></numberingGroup><correspondenceTo>Weill Cornell Medical College, Department of Neurology and Neuroscience, 428 East 72nd Street, Suite 400, New York, NY 10021</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20757.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="33"></count><count type="wordTotal" number="3660"></count></countGroup><titleGroup><title type="main" xml:lang="en">Compulsive eating and weight gain related to dopamine agonist use</title><title type="short" xml:lang="en">Compulsive Eating and Dopamine Agonist Use</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Melissa J.</givenNames><familyName>Nirenberg</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>mjnirenb@med.cornell.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Cheryl</givenNames><familyName>Waters</familyName><degrees>MD, FRCP(C)</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">dopamine agonist</keyword><keyword xml:id="kwd3">compulsive eating</keyword><keyword xml:id="kwd4">binge</keyword><keyword xml:id="kwd5">weight gain</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Dopamine agonists have been implicated in causing compulsive behaviors in patients with Parkinson's disease (PD). These have included gambling, hypersexuality, hobbyism, and other repetitive, purposeless behaviors (“punding”). In this report, we describe 7 patients in whom compulsive eating developed in the context of pramipexole use. All of the affected patients had significant, undesired weight gain; 4 had other comorbid compulsive behaviors. In the 5 patients who lowered the dose of pramipexole or discontinued dopamine agonist treatment, the behavior remitted and no further weight gain occurred. Physicians should be aware that compulsive eating resulting in significant weight gain may occur in PD as a side‐effect of dopamine agonist medications such as pramipexole. Given the known risks of the associated weight gain and obesity, further investigation is warranted. © 2005 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Compulsive eating and weight gain related to dopamine agonist use</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Compulsive Eating and Dopamine Agonist Use</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Compulsive eating and weight gain related to dopamine agonist use</title></titleInfo><name type="personal"><namePart type="given">Melissa J.</namePart><namePart type="family">Nirenberg</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</affiliation><description>Correspondence: Weill Cornell Medical College, Department of Neurology and Neuroscience, 428 East 72nd Street, Suite 400, New York, NY 10021</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cheryl</namePart><namePart type="family">Waters</namePart><namePart type="termsOfAddress">MD, FRCP(C)</namePart><affiliation>Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2006-04</dateIssued><dateCaptured encoding="w3cdtf">2005-03-11</dateCaptured><dateValid encoding="w3cdtf">2005-08-08</dateValid><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">3</extent><extent unit="references">33</extent><extent unit="words">3660</extent></physicalDescription><abstract lang="en">Dopamine agonists have been implicated in causing compulsive behaviors in patients with Parkinson's disease (PD). These have included gambling, hypersexuality, hobbyism, and other repetitive, purposeless behaviors (“punding”). In this report, we describe 7 patients in whom compulsive eating developed in the context of pramipexole use. All of the affected patients had significant, undesired weight gain; 4 had other comorbid compulsive behaviors. In the 5 patients who lowered the dose of pramipexole or discontinued dopamine agonist treatment, the behavior remitted and no further weight gain occurred. Physicians should be aware that compulsive eating resulting in significant weight gain may occur in PD as a side‐effect of dopamine agonist medications such as pramipexole. Given the known risks of the associated weight gain and obesity, further investigation is warranted. © 2005 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>dopamine agonist</topic><topic>compulsive eating</topic><topic>binge</topic><topic>weight gain</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>524</start><end>529</end><total>6</total></extent></part></relatedItem><identifier type="istex">47AAA15FC13290DBB65351837B9A150C1079A72B</identifier><identifier type="DOI">10.1002/mds.20757</identifier><identifier type="ArticleID">MDS20757</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A69 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002A69 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:47AAA15FC13290DBB65351837B9A150C1079A72B
|texte= Compulsive eating and weight gain related to dopamine agonist use
}}
| This area was generated with Dilib version V0.6.23. |  |